Pervasip Corp (PVSP)

[Bjones2]

Bipartisan ‘DANK Cannabis Research’ Bill Filed In Congress

This is Huge for Medical cannabis research, makes federal grants available for studies. Our minority owned KRTL Biotech will be doing research using Artizen genetically patented cannabis strains designed for various medical issues such as depression, various forms of cancer, etc. Huge dollar potential in Medical cannabis, which becomes legal pharmaceutical product and we know what pharmaceutical companies can charge for their prescription products. $$$$


Bipartisan ‘DANK Cannabis Research’ Bill Filed In Congress (Really)Published 15 hours ago on July 28, 2022By Kyle Jaeger

A bipartisan duo of congressional lawmakers filed a bill on Wednesday to set a federal marijuana research agenda and create a designation for universities to carry out cannabis studies with federal grant money.

The legislation from Reps. Scott Peters (D-CA) and Dave Joyce (R-OH) is titled the “Developing and Nationalizing Key Cannabis Research Act.” The bill text doesn’t abbreviate the title, so it’s not clear if the intent was to play into cannabis consumer nomenclature with the introduction of the DANK Cannabis Research Act.

In any case, the measure would require the National Institutes on Health (NIH) to collaborate with other agencies, including the Centers for Disease Control and Prevention (CDC) and Substance Abuse and Mental Health Services Administration (SAMHSA) to develop “a national cannabis research agenda that addresses key questions and gaps in evidence.”

That agenda must include six primary research objectives. For example, the agencies must prioritize studies into the safety and efficacy of cannabis in the treatment of multiple conditions such as epilepsy, multiple sclerosis, chemotherapy-related pain and nausea, as well as the use of marijuana as an opioid alternative.

Other agenda items include research into the effects of cannabis on “at-risk populations” like children and pregnant women, the “nontherapeutic impacts” of marijuana, the relationship between cannabis use and behavioral health, the “clinically appropriate dosages and modes of delivery of cannabis” and other public safety considerations related to potency, youth access and misuse

.https://www.marijuanamoment.net/bipartisan-dank-cannabis-research-bill-filed-in-congress-really/